Navigation Links
ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
Date:11/5/2009

on. We are also taking active steps, both in concert with another industry participant, and on our own, to drive further awareness in the primary care community of the health dangers of sleep-disordered breathing through educational programs. These efforts should further enlighten both doctors and patients especially with respect to the relationship between sleep-disordered breathing/obstructive sleep apnea and co-morbidities such as cardiac disease, diabetes, hypertension and obesity as well as the dangers of sleep apnea in regard to occupational health and safety, especially in the transport industry."

About ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. US Pacific Time today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's Web site at www.resmed.com or by dialing (866) 700-7173 (domestic) or +1 (617) 213-8838 (international) and entering conference I.D. No. 58367514. Please allow extra time prior to the call to visit the Web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing (888) 286-8010 (domestic) and +1 (617) 801-6888 (international) and entering conference I.D. No. 96602021.

Further information can be obt
'/>"/>

SOURCE ResMed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
6. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
9. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Quarter 2011 2011 Fourth Quarter Total Revenue $688.5 million; ... forma organic growth, excluding the impact of foreign exchange and acquisitions, was 10% ... 2011 Fourth Quarter GAAP Operating Cash Flow $190 million; Adjusted Operating ... Total 2011 revenue was $2.46 billion ...
... Inc., (NASDAQ: DCTH ) announced today that ... the Delcath Hepatic CHEMOSAT ® Delivery System at ... treatment and research center located in Frankfurt. The cases were ... agreement the Company announced with the hospital in December ...
Cached Medicine Technology:Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 2Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 3Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 4Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 5Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 6Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 7Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 8Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 9Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 10Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 11Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 12Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 13Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 14Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 15Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 16Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 17Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 18Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 19Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
... Aggression, testosterone and nepotism dont necessarily help one climb ... female can, according to new research on the social ... The study, published today in the journal Proceedings of ... status, reproductive physiology and group dynamics. , ...
... Hopkins researchers question government decision to lower requirements ... -- Challenging a recent U.S. government decision to ... heart transplant hospital, a new Johns Hopkins Medical ... from 10 transplants to 14 transplants a year. ...
... new study from the Monell Center increases understanding ... and vomiting that often afflict patients undergoing chemotherapy. ... new approaches to combat these debilitating side effects. ... nausea and vomiting that accompany chemotherapy treatment, we ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... 2008 Preventative heart healthcare gains strong momentum today ... involvement as the exclusive radiology provider for the High-Risk ... joint research effort to advance the understanding and management ... primary underlying cause of heart attacks and strokes. ...
... to Nutrition on the Go, an,innovative new program from Diet.com, ... 1,700 restaurants nationwide is available in,a flash through your cell ... item., Not cell phone savvy? No worries. You put ... you need help with, then send that info to,DIET1 (34381). ...
Cached Medicine News:Health News:Females decide whether ambitious males float or flounder 2Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: